Liquidia Corporation (NASDAQ:LQDA - Get Free Report) Director Stephen Bloch sold 25,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $79.47, for a total value of $1,986,750.00. Following the transaction, the director owned 855,073 shares of the company's stock, valued at approximately $67,952,651.31. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Liquidia Stock Up 0.4%
Shares of NASDAQ:LQDA opened at $79.21 on Tuesday. The firm has a market cap of $7.04 billion, a PE ratio of 565.83 and a beta of 0.55. The company has a fifty day simple moving average of $61.61 and a 200 day simple moving average of $45.70. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12-month low of $11.86 and a 12-month high of $80.98.
Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm's revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, equities research analysts anticipate that Liquidia Corporation will post 3.02 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. BTIG Research lifted their price target on Liquidia from $59.00 to $109.00 and gave the stock a "buy" rating in a research note on Monday, June 22nd. Raymond James Financial restated a "strong-buy" rating and set a $68.00 price objective on shares of Liquidia in a research note on Thursday, June 4th. HC Wainwright increased their target price on Liquidia from $67.00 to $75.00 and gave the stock a "buy" rating in a report on Friday, June 5th. Bank of America reiterated a "neutral" rating and issued a $79.00 target price (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Finally, Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $68.88.
View Our Latest Report on Liquidia
Hedge Funds Weigh In On Liquidia
A number of large investors have recently bought and sold shares of LQDA. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia in the fourth quarter valued at approximately $25,000. NewEdge Advisors LLC bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $25,000. FNY Investment Advisers LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $34,000. Covestor Ltd boosted its position in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company's stock valued at $42,000 after purchasing an additional 359 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Liquidia by 281.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company's stock valued at $83,000 after purchasing an additional 4,927 shares during the period. Institutional investors own 64.54% of the company's stock.
About Liquidia
(
Get Free Report)
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
